For Immediate Release DIMERIX QUARTERLY ACTIVITIES REPORT Highlights and Operational Activities Commercial Execution & Funding • Received A$14.1 million upfront payment from Everest Medicines under Dimerix's fifth regional 1 licensing agreement for DMX-200 o >A$80 million received in aggregate...